scholarly journals Quantitative Assessment of Effect of Preanalytic Cold Ischemic Time on Protein Expression in Breast Cancer Tissues

2012 ◽  
Vol 104 (23) ◽  
pp. 1815-1824 ◽  
Author(s):  
V. M. Neumeister ◽  
V. Anagnostou ◽  
S. Siddiqui ◽  
A. M. England ◽  
E. R. Zarrella ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Quantitative Assessment ◽  
Ischemic Time ◽  
Cold Ischemic Time ◽  
Cancer Tissues

scholarly journals Metabotropic glutamate receptor 1 is associated with unfavorable prognosis in ER-negative and triple-negative breast cancer

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Anna E. M. Bastiaansen ◽  
A. Mieke Timmermans ◽  
Marcel Smid ◽  
Carolien H. M. van Deurzen ◽  
Esther S. P. Hulsenboom ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Glutamate Receptor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Metabotropic Glutamate Receptor ◽  
Metabotropic Glutamate ◽  
Metabotropic Glutamate Receptor 1 ◽  
Novel Target ◽  
Cancer Tissues

AbstractNew therapies are an urgent medical need in all breast cancer subgroups. Metabotropic glutamate receptor 1 (mGluR1) is suggested as a potential new molecular target. We examined the prevalence mGluR1 expression in different clinically relevant breast cancer subgroups and determined its association with prognosis. In this retrospective cohort, 394 consecutive primary breast cancer tissues were incorporated into a tissue microarray and immunohistochemically stained for mGluR1. The prevalence of mGluR1 protein expression in different breast cancer subgroups was evaluated and correlated with metastasis-free survival (MFS) and overall survival (OS). In total, 56% (n = 219) breast cancer tissues had mGluR1 expression. In estrogen receptor (ER)-negative tumors, 31% (n = 18/58) had mGluR1 expression that was significantly associated with MFS (HR 5.00, 95% CI 1.03–24.35, p = 0.046) in multivariate analysis, independently from other prognostic factors. Of the 44 triple-negative breast cancer (TNBC), 25% (n = 11) expressed mGluR1. mGluR1 expression in TNBC was significantly associated with shorter MFS (HR 8.60, 95% CI 1.06–20.39, p = 0.044) and with poor OS (HR 16.07, 95% CI 1.16–223.10, p = 0.039). In conclusion, mGluR1 is frequently expressed in breast cancer. In ER-negative breast cancer and in TNBC mGluR1 protein expression is an unfavorable prognostic marker. This study provides rationale to explore mGluR1 as a novel target for breast cancer treatment, especially for the more aggressive TNBC.

scholarly journals Impact of Cold Ischemic Time and Freeze-Thaw Cycles on RNA, DNA and Protein Quality in Colorectal Cancer Tissues Biobanking

2019 ◽  
Vol 10 (20) ◽  
pp. 4978-4988
Author(s):  
Xin-Juan Fan ◽  
Yan Huang ◽  
Pei-Huang Wu ◽  
Xin-Ke Yin ◽  
Xi-Hu Yu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Protein Quality ◽  
Ischemic Time ◽  
Freeze Thaw ◽  
Cold Ischemic Time ◽  
Cancer Tissues

Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11009-e11009
Author(s):  
Zafer Arik ◽  
Sercan Aksoy ◽  
Mehmet Ali Nahit Sendur ◽  
Sebnem Yaman ◽  
Kadri Altundag
Keyword(s):  
Breast Cancer ◽  
Surgical Procedure ◽  
False Negative ◽  
Radical Mastectomy ◽  
The Other ◽  
Breast Cancer Patients ◽  
Ischemic Time ◽  
Cold Ischemic Time ◽  
Her 2 ◽  
Expression Status

e11009 Background: Estrogen receptor (ER), progesteron receptor (PR) and HER-2 are prognostic and predictive markers in the management of breast cancer treatment. Delay in fixation of the specimens may reduce the ability to detect breast cancer biomarkers and resulting in false negative immunhistochemical results. Handling of specimens from operation rooms to pathology laboratories may delay sometimes, especially Fridays. We hypothesized that ER, PR and HER-2 expression status may change according to the day of surgical procedure. Methods: Patients who operated between 2005 and 2010 for breast cancer in our Hospital were analyzed retrospectively. Consecutive 462 patients who had breast conserving surgery and modified radical mastectomy were included into the study. Patient’s demographics data and tumor characteristics and surgical procedure day were obtained from medical charts. Results: The mean age of the study population was 50±11 years. There were not differences between the T, N, M stage and age of patients according to operation day. ER, PR, HER-2 expressions were similar in Monday, Tuesday, Wednesday and Thursday. So we grouped the patients operated on Friday and others. Among the patients, 121 (26%) were operated on Friday. ER and PR negativity was higher on Friday procedures than the other weekdays (40% vs 23.2%; p=0.008 and 35.7% vs 27.9%; p=0.08, respectively). HER-2 positivity on Friday was significantly higher than the other weekdays (41.9% versus 23.4%; P=0.005). Conclusions: Cold ischemic time is the interval between removal of the tissue and placement in the tissue fixative. ER and PR are thermolabile proteins whose levels of expression are altered by prolonged cold ischemic time. Studies have shown delays in handling of breast cancer tissues affect biomarkers positivity and some tumors were classified falsely as negative. Specimens obtained on Friday may have more delaying for handling; therefore may have more hormon receptor negative results. In our study we have shown that ER negativity and HER-2 positivity are significantly higher on patients who were operated on Friday. Our study showed that handling of the specimen to the pathology laboratories is crucial and affect the treatment decisions.

Comprehensive Analysis of the Expression and Prognostic Significance of THBSs in Breast Cancer

2021 ◽  
Author(s):  
Jun Wang ◽  
Xuebing Zhan ◽  
Qian Luo ◽  
Yunshu Kuang ◽  
Xiao Liang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Protein Expression ◽  
Cancer Patients ◽  
Prognostic Value ◽  
Breast Cancer Patients ◽  
Free Survival ◽  
Expression Levels ◽  
Cancer Tissues ◽  
Mrna Expression Levels

Abstract Background: Breast cancer is one of the most common tumors for women worldwide. Thrombospondins (THBSs) are reported to play important roles in various cellular processes and are involved in the occurrence and development of human cancers. However, the expression and prognostic value of THBSs family in breast cancer remain unclear.Methods: In this study, we examined the genes and protein expression levels of THBSs and their prognostic value by synthesizing several mainstream databases, including Oncomine, Human Protein Atlas (HPA), UALCAN, and KM Plotter. We also analyzed THBS interaction networks, genetic alterations, functional enrichment, and drug sensitivity with several publicly accessible databases, including GEPIA, GeneMANIA, STRING, cBioPortal, Metascape and NCI-60 database.Results: The results showed that the mRNA expression levels of THBS1, THBS2, THBS3, and THBS5 in breast cancer tissues were significantly higher than in normal tissues. The mRNA expression levels of THBS4 were different in different subtypes of breast cancer, and the protein expression levels of THBS1, THBS2, and THBS4 in breast cancer tissues were higher than in normal breast tissues. Survival analysis showed that breast cancer patients with high THBS1 gene expression showed worse overall survival (OS), relapse-free survival (RFS), and post-progression survival (PPS), and breast cancer patients with high THBS2 gene expression also showed worse RFS. Conversely, lower THBS3 levels predicted worse RFS, and lower THBS4 levels predicted worse OS, RFS, and distant metastasis-free survival (DMFS). Conclusions: These results suggest that THBSs may be potential biomarkers for breast cancer.

scholarly journals Downregulated expression of ARHGAP10 correlates with advanced stage and high Ki-67 index in breast cancer

PeerJ ◽  
2019 ◽  
Vol 7 ◽  
pp. e7431
Author(s):  
Yujing Li ◽  
Beilei Zeng ◽  
Yunhai Li ◽  
Chong Zhang ◽  
Guosheng Ren
Keyword(s):  
Breast Cancer ◽  
Protein Expression ◽  
Rho Gtpase ◽  
Excision Repair ◽  
Gene Set Enrichment Analysis ◽  
Ki 67 ◽  
Normal Tissues ◽  
Response To Chemotherapy ◽  
Cancer Tissues ◽  
Low Expression

Background Rho GTPase-activating protein 10 (ARHGAP10), which catalyzes the conversion of active Rho GTPase to the inactive form, is downregulated in some cancers. However, little is known about ARHGAP10 in breast cancer. Methods The transcriptional expression level of ARHGAP10 in breast cancer was analyzed with the data downloaded from The Cancer Genome Atlas (TCGA) and Oncomine, then verified by reverse-transcription quantitative polymerase chain reaction (RT-qPCR) in 30 pairs of breast cancer tissues and the corresponding adjacent normal tissues. ARHGAP10 protein expression was examined by immunohistochemistry (IHC) in 190 breast cancer and 30 corresponding adjacent normal breast tissue samples. The associations between ARHGAP10 expression and clinicopathological characteristics of patients were analyzed, and Kaplan–Meier Plotter was used to assess the relationship between ARHGAP10 and relapse-free survival (RFS). Different expression levels of ARHGAP10 in response to chemotherapy agents were determined by GEO2R online tool. The potential biological functions of ARHGAP10 were analyzed by Gene Set Enrichment Analysis (GSEA) using data downloaded from TCGA. Results ARHGAP10 mRNA and protein expression was lower in breast cancer tissues than in adjacent normal tissues. Low expression of ARHGAP10 was associated with advanced clinical TNM (cTNM) stage (pb = 0.001) and high Ki-67 index (p = 0.015). Low expression of ARHGAP10 indicated worse RFS (p = 0.0015) and a poor response to chemotherapy (p = 0.006). GSEA results showed that ARHGAP10 was involved in signaling pathways including protein export, nucleotide excision repair, base excision repair, focal adhesion, JAK-STAT pathway and the actin cytoskeleton.

Sign in / Sign up

Export Citation Format

Share Document